Vaccine schedule in the spotlight as UK ramps up distribution

4 January 2021

Days after the UK government announced it would alter the schedule for the country’s coronavirus vaccine program, healthcare experts continue to debate the wisdom of deviating from the approved timeline.

Last week, the UK medicines regulator became the first authority to approve the AstraZeneca (LSE: AZN) and Oxford University vaccine for emergency use, with a second dose OK’d for delivery “between 4 and 12 weeks after the first.”

The Medicines and Healthcare products Regulatory Agency (MHRA) also said that, based on the data it had reviewed, the Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) vaccine, BNT162b2, should be given in doses spaced “at least 3 weeks” apart.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK